The Scarcity You Can't Borrow Back

The treatise has a section that no dispatch has applied yet. Section VII, The Temporal Axis, makes a specific and uncomfortable argument: the acute monetary scarcity of a Minsky crisis is counterfeit, a manufactured shortage that leaves the real productive base physically intact. But it comes with a time limit. If the acute scarcity is not relieved quickly, it stops being counterfeit. It begins to destroy the capacity it was only pretending to threaten. Factories are scrapped for salvage. Skilled workers disperse and their skills atrophy. The knowledge embedded in going concerns evaporates when those concerns are liquidated. What began as a financial illusion hardens into genuine poverty, permanent rather than temporary, no longer reversible by an emergency liquidity injection because the thing the liquidity would have saved is gone.

The current program of cuts to the CDC, NIH, and federal research funding is that mechanism operating on a different class of asset. Public health infrastructure is not a factory. What it produces is not a good in the ordinary sense. What it produces is the capacity to detect, contain, and prevent the next real scarcity, the next pandemic, the next foodborne outbreak, the next antibiotic-resistant pathogen spreading through a conflict zone. Destroy that capacity under the banner of fiscal discipline, and you have not saved money. You have deferred an enormous real cost while eliminating the one institution built to keep that cost from arriving. The monetary scarcity was counterfeit. The public health scarcity you have manufactured in its place is not.

The manager parallel

The treatise makes another argument that transfers directly. Section V names the central bank as the scarcinality manager, the institution whose task is to prevent financial scarcity from seizing the top rank and propagating downward. The treatise is specific about why this manager must exist and be credible before the crisis: in the acute dash for cash, the days and weeks that determine whether a financial freeze becomes a depression, the only effective intervention is one that arrives immediately and is believed instantly. An institution that has been politically bent, publicly doubted, or organizationally hollowed out cannot perform that function on schedule. Its credibility is a reserve accumulated over decades; it is spent down each time the institution is subordinated to a short-term political goal.

The CDC is the scarcinality manager for the real layer of public health. Its function is precisely analogous: to detect the early signal of an emerging real scarcity, a novel pathogen, a foodborne outbreak, an antibiotic resistance pattern spreading through a hospital system, and intervene before it propagates downward into a genuine goods-layer shock. That early detection is worth most in the first days and weeks of an outbreak, before the pathogen has established itself in the population. Speed requires standing capacity: a surveillance network already deployed, a laboratory system already calibrated, a trained workforce that already knows the protocols. These are the reserve. They cannot be reconstituted in the weeks when they are needed, for exactly the same reason the central bank's credibility cannot be rebuilt in the middle of a bank run.

What is being cut

The proposed FY2026 budget reduces the CDC by 53 percent, from approximately $9.2 billion to $4.3 billion, and eliminates over sixty programs. The agency's staff of 13,363 as of 2024 would be reduced by 43 percent, to 7,571. More than 1,300 employees were laid off in the early months of 2025; on April 1 of that year, more than 90 percent of the staff at the National Institute for Occupational Safety and Health received layoff notices. More than eleven billion dollars in COVID-19 preparedness grants, funds that had been building out laboratory capacity, emergency response infrastructure, and infectious disease monitoring networks across fifty state and territorial health departments, were clawed back. The Foodborne Diseases Active Surveillance Network, which had tracked eight pathogens, was reduced to tracking two: salmonella and Shiga toxin-producing E. coli. Campylobacter, listeria, shigella, vibrio, yersinia, and cyclospora dropped from the active list on July 1, 2025.

NIH would see its discretionary budget cut by roughly 40 percent, from $46 billion to $27.9 billion, with grant funding reduced by 43 percent. Separately, the administration attempted to cap reimbursement of indirect research costs, the laboratory maintenance, equipment depreciation, compliance infrastructure, and support staffing that make federally funded research physically possible, at 15 percent, against a previously negotiated average of 28 percent and rates above 60 percent at research-intensive universities. A federal court permanently enjoined that cap, and Congress blocked its implementation in several appropriations bills. The legal defeat did not erase the policy signal: institutions froze hiring, deferred capital investment, and began restructuring research programs against the possibility that the legal protection would not persist.

The asymmetry

There is a number that frames the whole question, and the framework's insistence on falsifiability requires it be stated plainly. Harvard economists estimated the cumulative financial cost of the COVID-19 pandemic to the United States at more than $16 trillion in lost output and reduced health. The combined CDC and NIH spending on public health infrastructure and research, not just pandemic-specific, but across the entire portfolio of disease surveillance, prevention, and biomedical science, ran in the range of $55 billion per year in 2024, representing roughly 0.2 percent of GDP. The pandemic's economic cost was roughly 290 years of that entire annual budget.

The framework's reading of this arithmetic is not that the prevention budget is obviously the right size. It is that the argument for cutting it rests on a confusion between the scarcity types. The deficit is a financial scarcity, a constraint on how many dollars the government spends. That constraint is real in a fiscal sense. But the CDC and NIH are not financial instruments. They are prevention capacity. Cutting them to relieve a financial constraint manufactures a genuine capacity scarcity in exchange for a temporary easing of a monetary one. It is the treatise's central mechanism: the counterfeit scarcity of money hardening into the genuine scarcity of the thing money was cutting. The only question is whether the genuine scarcity that forms in the interval costs more than the monetary scarcity it was traded for. The pandemic's price tag makes the answer to that question straightforward.

The wars and the real bind

The treatise's worked example of 2025–2026 acknowledges a foreign conflict driving an energy shock. There are now two active wars of consequence to the US position in global commodity and health markets, and both are relevant to what the framework calls the real bind layer.

Ukraine remains the world's largest exporter of sunflower oil and a major exporter of wheat and corn. When the conflict began in 2022, global wheat futures jumped roughly 60 percent within days of the war's onset. By 2025, Russia had enlarged its share of global grain exports while Ukraine's production capacity remained constrained, roughly 45 percent of Ukrainian agricultural exports now move via overland solidarity corridors rather than Black Sea shipping. The real scarcity of wheat in price-sensitive import-dependent nations, North Africa, the Middle East, parts of sub-Saharan Africa, is not counterfeit. It is the direct consequence of the war disrupting a supply node. The secondary risk that the framework flags is the one the CDC would have been best positioned to detect: conflict zones are where antibiotic-resistant pathogens, cholera, typhoid, and novel respiratory viruses first establish population-level reservoirs. A dismantled US global surveillance network is less likely to detect the early signal from a Ukrainian hospital or a Syrian refugee camp. The real scarcity of wheat in the conflict zone and the real risk of disease spreading from it are not separate problems. They share the same institutional address: the CDC's Global Disease Detection network, which was among the programs facing reorganization and funding reduction in 2025.

The Iran conflict added an oil shock. Crude prices rose above $90 a barrel after the conflict escalated in early 2026. The energy-price channel feeds directly into the stagflation configuration of the treatise's Section VIII, pressing goods-side costs upward at precisely the moment the monetary layer remains under pressure. Iran also sits at the intersection of several antimicrobial resistance transmission routes; it is a major transit country for pathogens moving between Central Asia, South Asia, and the Mediterranean. The specific expertise that allows the CDC to run field investigations in conflict-adjacent territories, already reduced, is the capacity most at risk when surveillance staff are laid off and global health programs are eliminated.

The capacity that disperses

The treatise says precisely what to watch for. In the chronic phase of a capacity-destruction event, the losses are not visible in a budget line. They are visible in the dispersal of human expertise. An epidemiologist who leaves the CDC's influenza surveillance division after the April 2025 layoffs does not retire the knowledge she carried. She takes a position in a hospital system, a consulting firm, or a foreign health ministry. The expertise does not vanish, but the network it was embedded in does. A surveillance system is not a list of names. It is a web of relationships, between field investigators who know each other, between laboratory directors who have worked together through prior outbreaks, between state health officers and federal specialists who have the kind of institutional trust that allows a phone call at 2 a.m. to trigger a coordinated response. That web is built over years of shared work and calibrated through the small outbreaks that never became crises because the system caught them early. It cannot be rebuilt by an appropriations bill. It can only be regrown, slowly, through the same decades of shared practice that built it originally.

The university research pipeline follows the same logic. A doctoral student in infectious disease epidemiology who begins a program in 2024 will complete it in 2029 or 2030, if their funding survives. The proposed NIH cuts, 43 percent of grant funding, mean a large share of those students will not complete their programs, or will complete them without the postdoctoral positions that convert a degree into an operational researcher. The research they do not produce cannot be undone later by additional funding. The compound effect of a scientific career interrupted at its foundation is not measurable in the year the cut is made; it is measurable in the decade it foreclosed. The treatise names this the chronic phase precisely because the damage is not immediate and therefore not politically visible until it is too late to reverse.

The tariff compounding

The same administration that is cutting the CDC and NIH has imposed tariffs on scientific instruments, laboratory materials, and specialty equipment largely manufactured in Europe and Asia. The indirect cost cap, even temporarily enjoined, sent a signal to universities that their administrative and infrastructure costs would not be covered at negotiated rates. The result is a double compression: funding for research is reduced from the grant side, and the cost of conducting research is increased from the tariff and compliance side. A laboratory that was viable at full indirect cost reimbursement and no tariffs on its centrifuges and sequencing reagents is not necessarily viable at 15 percent indirect coverage and a 25 percent tariff on its capital equipment. The tariff manufactures a cost-side scarcity to compound the funding-side scarcity. Both levers press on the same research capacity simultaneously.

The falsifiable predictions

The framework makes specific, dated, conditional claims.

One: The reduction of FoodNet's surveillance from eight pathogens to two will result in at least one major foodborne outbreak, campylobacter, listeria, shigella, vibrio, or yersinia, being identified later than it would have been under the full surveillance network. Later identification means more cases before containment. The economic cost of the additional cases will exceed, in the year they occur, the full annual operating budget of the FoodNet program that would have detected the outbreak earlier. The measurable form: the median case count at the time of outbreak identification for the six dropped pathogens will rise relative to the 2015–2024 FoodNet baseline. The prediction is falsified if identification speed for those pathogens holds at or near the baseline through 2028.

Two: The dispersal of CDC field epidemiology staff in 2025 will extend the detection-to-response interval for the next novel pathogen event by a measurable duration, weeks rather than days, compared to what the pre-2025 network would have achieved. The benchmark is the 2014 Ebola response, when the CDC deployed staff to West Africa within days of the initial alert and ultimately sent more than 1,400 responders over the course of the epidemic. The proposed staffing levels make an equivalent response impossible within the same timeframe. This prediction is falsified if the reorganized agency demonstrates equivalent or superior response speed in the next significant outbreak.

Three: The long-run cost of the NIH grant cuts will exceed the nominal savings within fifteen years, as the pipeline of trained researchers fails to produce the therapies, diagnostic tools, and preventive interventions that would have reduced chronic disease burden. The Congressional Budget Office scores drug pricing and prevention spending against static projections; it does not score the research capacity that produces drugs that haven't been invented yet. The framework's claim is that this omission systematically understates the cost of cutting research funding, because the benefit of research is precisely the real scarcity it prevents from forming in the future.

What the framework concludes

The treatise says the scarcinality manager must exist and be credible before the crisis, because it cannot be built during one. The CDC's credibility, its network, its field capacity, and its institutional memory are that manager's analog for the public health layer. The cuts being made now are not a response to a crisis. They are being made in what the treatise would call the tranquil phase, the period when the Minsky logic says the structure is quietly migrating toward fragility. Cutting the manager in tranquility is precisely the mistake the treatise identifies: drawing down the very reserve that the next emergency will require, before the emergency arrives to test it.

One honest qualification. The treatise's Section VII mechanism is credit-driven: unrelieved financial scarcity from a crisis destroying capacity through distress and liquidation. What is happening to the CDC and NIH is a deliberate legislated cut in a tranquil period, not a credit contraction. The dispatch applies the mechanism by analogy, and the analogy should be stated rather than smuggled: the claim is that policy-imposed austerity and unrelieved credit scarcity destroy capacity through the same channel, the dispersal of embedded knowledge and the interruption of pipelines that take decades to build, even though the proximate cause differs. Similarly, the treatise treats deficit pressure at the long end of the bond curve as genuine financial scarcity, not counterfeit; this dispatch does not dispute that. Its claim is narrower: whatever the reality of the fiscal constraint, relieving it by destroying irreplaceable prevention capacity trades a recoverable scarcity for an unrecoverable one.

The financial argument for the cuts holds that the deficit is a real scarcity that must be addressed. The framework's reply is that a budget deficit is a monetary scarcity of government funds, real within its own layer, but counterfeit relative to the physical capacity being traded for it. The CDC surveillance network, the NIH research pipeline, the university scientific infrastructure: none of these is a financial instrument. They are real productive capacity of a specific and irreplaceable kind. Cutting them to address a monetary constraint does not make the monetary constraint disappear. It manufactures a genuine real scarcity downstream, at a cost that will be paid in a future quarter when the next outbreak arrives, the next antibiotic fails, or the next pandemic spreads for three additional weeks before the detection network catches it.

The factories stand. The shelves are full. The warehouses are stocked. Whether the people go without depends not on the goods but on the rank that money holds. The treatise's final sentence. The public health version runs the same way. The knowledge exists. The surveillance is possible. Whether the disease spreads unchecked depends not on the pathogen but on whether the institution built to detect it was still running when it arrived.